Eli Lilly joins SNM imaging network
Eli Lilly has joined SNM’s Clinical Trials Network, a collaborative effort designed to address the need for validated imaging biomarkers for streamlining the development and registration of investigational therapeutics.
Eli Lilly has joined SNM's Clinical Trials Network, a collaborative effort designed to address the need for validated imaging biomarkers for streamlining the development and registration of investigational therapeutics.
The network also applies for and holds FDA new drug applications that will be available for cross-reference in multicenter clinical trials of imaging agents to assess response to treatment or to stratify patients for enrollment in clinical trials. "Eli Lilly seeks to improve patient outcomes by accelerating our therapeutic pipeline by using molecular imaging," said Johannes Tauscher, MD, a medical fellow and head of the translational imaging group at the company.
![Radiotherapy is a very evidence-based subject. We can tell quite accurately how well we think [a patient] is going to do.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Feecaffda6ab0cbb4f4463586ace2f199eeefa8bf-400x401.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "Radiotherapy is a very evidence-based subject. We can tell quite accurately how well we think [a patient] is going to do.")
